Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

However, at a 2.7-year follow-up of the Phase I study, 48% of patients reported adverse vascular events. At a follow-up of the Phase II study (median time of 1.3 years), 24% of patients had an MI, stroke, limb ischemia, or stenosis of the vessels of the heart, extremities or brain requiring revascularization.38 It is unlikely that these events can be fully explained by underlying cardiovascular risk, as numbers this high were not seen in late phase trials of other TKIs. Further, adverse events occurred as soon as two weeks into therapy and even in patients with no cardiovascular risk factors.38